Biopharmaceutical Sector Update on the Financing and Deal ... - Torreya

Global Biopharmaceuticals M&A Volume, Q1 2014 to Q2 2020 16 Commercial Stage Pharma M&A Deals, 2020 17 ... We found that if three stocks were omitted from the index, the returns for the year would have been 60% less. The stocks were Gilead, Moderna and Regeneron. All three companies have had outstanding returns due to their ................
................